Podcast Episode 27: Scrutinizing One of Our Longest-Funded Programs

Key Takeaways

• Original trials show 19% mortality reduction
• Updated analysis estimates 1‑11% reduction today
• Cost‑effectiveness stays high, 25× benchmark
• Study addressed publication bias and dosing frequency
• GiveWell considers new randomized trial for vitamin A

Pulse Analysis

Vitamin A supplementation has been a cornerstone of global child‑health strategies for decades, driven by early randomized controlled trials that linked the micronutrient to sizable mortality reductions. Those studies, conducted when infectious disease burdens and vitamin A deficiency were markedly higher, established a 19% average risk‑reduction figure that guided funding decisions worldwide. As the epidemiological landscape shifts, however, the relevance of those historic results to today’s lower‑prevalence contexts has become a critical question for donors and policymakers alike.

GiveWell’s latest deep‑dive leverages a novel dosing‑frequency analysis, expert statistical consultation, and a systematic review for publication bias to recalibrate the program’s expected impact. The revised model now projects a 1%‑11% mortality reduction for children aged six to 59 months in the regions it currently funds, a substantial contraction from the original estimate. Nevertheless, the organization’s cost‑effectiveness calculations remain compelling, positioning vitamin A supplementation at roughly twenty‑five times its internal benchmark for value. This nuanced view allows GiveWell to allocate resources more precisely, targeting locations where the intervention promises the greatest health returns per dollar.

The broader lesson underscores the importance of iterative evidence appraisal within the effective‑altruism community. By openly revisiting assumptions and investing in fresh research—including the possibility of a new randomized trial—GiveWell reinforces a data‑driven culture that maximizes donor impact. For philanthropists seeking high‑return health interventions, the updated findings provide reassurance that even well‑established programs can benefit from rigorous, ongoing scrutiny, ensuring that funds continue to generate the most good possible.